BioSpace News Archive

Eli Lilly and Company will participate in the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019.

Cellectis announced that the first patient enrolled in the dose escalation Phase 1 clinical study for its UCART22 product candidate has been dosed at The University of Texas MD Anderson Cancer Center.

Piper Jaffray Companies, a leading investment bank and institutional securities firm, will host its 31st annual Healthcare Conference in New York on December 3-5, 2019.

The claims around PCM are to aid clinicians who are using Subjective Global Assessment (SGA) tools to assess patients at risk of PCM.

As the 13th member company elected into ACRO, Signant Health bring its unique voice and views on patient-centricity and trial technology to the forefront

Centene Corporation announced the extension of the expiration date of the offers to exchange notes issued by WellCare Health Plans, Inc.

Gastric Cancer Foundation Celebrates 10 Years Supporting the Gastric Cancer Community

The Council of the Federation meeting in Toronto, Canada’s First Ministers placed our health care system where it belongs: at top of the agenda.

Emerging mutations in patients with treatment resistance, from Phase 3 ADMIRAL study, will be focus of oral presentation

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced completion and positive results from the Phase 1 study of OSE-127, a humanized monoclonal antibody with a differentiated mechanism of action as a full-antagonist of the CD127 receptor, the alpha chain of the interleukin-7 receptor (IL-7R). OSE-127 has been shown in previous studies to induce a powerful antagonistic effect on effector T lymphocytes responsible for causing autoimmune diseases.